Brief: Inventiva SA Announces Initiation Of Phase III Clinical Trial Evaluating Lanifibranor In NASH
08/09/2021 21:12
Sept 8 (Reuters) - Inventiva SA IVAA.PA :
* INVENTIVA SA - ANNOUNCES INITIATION OF ITS PIVOTAL PHASE
III
CLINICAL TRIAL EVALUATING LANIFIBRANOR IN NASH
* INVENTIVA SA - PUBLICATION OF TOPLINE RESULTS OF PART 1 OF
TRIAL
IS EXPECTED FOR H2 2024
Source text for Eikon: ID:nGNX2WH0NB
Further company coverage: IVAA.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inventiva SA
See all newsFrance's Inventiva H1 net loss narrows
Brief: Euronext Includes Genfit, Inventiva In SBF120 Index; Interparfums, Verallia Excluded
Brief: Inventiva Announces Last Patient Visit In Nativ3 Phase 3 Clinical Trial Of Lanifibranor In Mash
Brief: Inventiva Announces Comprehensive Capital Structure Optimization Including Debt And Equity Financing In Advance Of The Anticipated Phase 3 Readout
Brief: Inventiva Secures Up To €150 Mln Debt Financing, Extends Debt Maturity To 2030